Evaluation of processing characteristics of photochemically treated pooled platelets: Target requirements for the INTERCEPT blood system comply with routine use after process optimization

Transfusion Medicine

Volumn 14, Issue 3, 2004, Pages 217-224

  Picker, Susanne M ^a   Speer, R ^a   Gathof, B S ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Blood processing; Pathogen inactivation; Platelet concentrates; Quality assessment

Indexed keywords

THROMBOCYTE CONCENTRATE;

ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; BLOOD TRANSFUSION; HUMAN; PHOTOCHEMISTRY; PROCESS OPTIMIZATION; PURIFICATION; QUALITY CONTROL; STANDARD; THROMBOCYTE;

EID: 3042595831     PISSN: 09587578     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0958-7578.2004.00503.x     Document Type: Article

References (20)

1. Allain, J.P. (2000) Will genome detection replace serology in blood screening for microbial agents? Bailliere's Clinical Haematology, 13, 615-629.
2. Blajchman, M.A. (2002) Incidence and significance of the bacterial contamination of blood components. In: Advances in Transfusion Safety-2001 (eds Brown, F. & Seitz, R.). Developments in Biologicals, 108, 59-67. Karger, Basel.
3. Council of Europe. (2002) Guide to the preparation, use and quality assurance of blood components. Council Of Europe Publishing, 8th edn, Strasbourg.
4. Council of Europe Expert Committee in Blood Transfusion Study Group on Pathogen Inactivation of Labile Blood Components. (2001) Pathogen inactivation of labile blood products. Transfusion Medicine, 11, 149-175.
5. Dodd, R.Y. (2000) Current viral risks of blood and blood products. Annals of Medicine, 32, 469-474.
6. Grass, J.A., Hei, D.J., Metchette, K., Cimino, G.D., Wiesehahn, G.P., Corash, L. & Lin, L. (1998) Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood, 91, 2180-2188.
7. Gulliksson, H. (2000) Additive solutions for the storage of platelets for transfusion. Transfusion Medicine, 10, 257-265.
8. Högman, C.F. (1996) Adverse effects: bacterial contamination (including shelf life). A brief review of bacterial contamination of blood components. Vox Sanguinis, 70S3, 78-82.
9. Janetzko, K., Klinger, M., Mayaudon, V., Lin, L., Eichler, H. & Klüter, H. (2002) Storage characteristics of split double-dose platelet concentrates derived from apheresis and treated with amotosalen-HCl and UVA light for pathogen inactivation. Infusion Therapy and Transfusion Medicine, 29, 193-198.
10. Knutson, F., Alfonso, R., Dupuis, K., Mayaudon, V., Lin, L., Corash, L. & Högman, C.F. (2000) Photochemical inactivation of bacteria and HIV in buffy-coat derived platelet concentrates under conditions that preserve in vitro platelet function. Vox Sanguinis, 78, 209-216.
11. Lin, R., Alfonso, R., Behrman, B., Corten, L., Damonte, P.B., Dikeman, R., Dupuis, K., Hei, D., Lin, C.Y., Londe, H.F., Metchette, K., Phan, T., Reames, A.A., Rheinschmidt, M., Savoor, A., Tessman, J. & Corash, L. (1998) Photochemical treatment of platelet concentrates with a novel psoralen and UVA to enhance the safety of platelet transfusions. Infusion Therapy and Transfusion Medicine, 25, 39-48.
12. Lin, L., Londe, H., Hanson, C.V., Wiesehahn, G., Isaacs, S., Ciminio, G. & Corash, L. (1993) Photochemical inactivation of cell-associated human immunodeficiency virus in platelet concentrates. Blood, 82, 292-297.
13. McDonald, C.P., Roy, A., Lowe, P., Robbins, S., Hartley, S. & Barbara, J.A. (2001) Evaluation of the BacT/Alert automated blood culture system for detecting bacteria and measuring their growth kinetics in leucodepleted and non-leucodepleted platelet concentrates. Vox Sanguinis, 81, 154-160.
14. Müller-Breitkreutz, K. (2000) Results of viral marker screening of unpaid donations and probability of window donations in. Vox Sanguinis, 78, 149-157.
15. Ness, P., Braine, H., King, K., Barrasso, C., Kickler, T., Fuller, A. & Blades, N. (2001) Single-donor platelets reduce the risk of septic platelet transfusion reactions. Transfusion, 41, 857-861.
16. Picker, S.M., Jedrzejewska, M., Giebel, F., Wassmer, G. & Gathof, B.S. (2002) Buffy-coat optimizing: an easy and effective step to improve quality of pool platelets. Infusion Therapy and Transfusion Medicine, 29, 44.
17. van Rhenen, D.J., Vermeij, J., Mayaudon, V., Hind, C., Lin, L. & Corash, L. (2000) Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy-coats. Vox Sanguinis, 79, 206-214.
18. van Rhenen, D., Gulliksson, H., Cazenave, J.P., Pamphilson, D., Ljungman, P., Klüter, H., Vermeij, H., Kappers-Klunne, M., de Greef, G., Laforet, M., Lioure, B., Davis, K., Marblie, S., Mayaudon, V., Flament, J., Conlan, M., Lin, L., Metzel, P., Buchholz, D. & Corash, L. (2003) Transfusion of pooled buffy-coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood, 101, 2426-2433.
19. Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie). (2000) Aufgestellt Vom Wissenschaftlichen Beirat der Bundesärztekammer und Vom. Paul-Ehrlich-Institut, Deutscher Ärzteverlag Köln.
20. Slichter, S. (2002) INTERCEPT platelets provide effective hemostasis and count increments: comparison to conventional platelets in two phase III clinical trials. Poster Presented at the 7th Annual Congress of the European. Hematology Association, Florence, Italy, June 2002.